4r5w
From Proteopedia
(Difference between revisions)
												
			
			| Line 3: | Line 3: | ||
| <StructureSection load='4r5w' size='340' side='right' caption='[[4r5w]], [[Resolution|resolution]] 2.84Å' scene=''> | <StructureSection load='4r5w' size='340' side='right' caption='[[4r5w]], [[Resolution|resolution]] 2.84Å' scene=''> | ||
| == Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[4r5w]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4R5W OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4R5W FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4r5w]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4R5W OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4R5W FirstGlance]. <br> | 
| </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=XAV:2-[4-(TRIFLUOROMETHYL)PHENYL]-7,8-DIHYDRO-5H-THIOPYRANO[4,3-D]PYRIMIDIN-4-OL'>XAV</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=XAV:2-[4-(TRIFLUOROMETHYL)PHENYL]-7,8-DIHYDRO-5H-THIOPYRANO[4,3-D]PYRIMIDIN-4-OL'>XAV</scene></td></tr> | ||
| <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4und|4und]], [[4uxb|4uxb]], [[4r6e|4r6e]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4und|4und]], [[4uxb|4uxb]], [[4r6e|4r6e]]</td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">ADPRT, PARP1, PPOL ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
| <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/NAD(+)_ADP-ribosyltransferase NAD(+) ADP-ribosyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.2.30 2.4.2.30] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/NAD(+)_ADP-ribosyltransferase NAD(+) ADP-ribosyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.2.30 2.4.2.30] </span></td></tr> | ||
| <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4r5w FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4r5w OCA], [http://pdbe.org/4r5w PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4r5w RCSB], [http://www.ebi.ac.uk/pdbsum/4r5w PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4r5w ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4r5w FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4r5w OCA], [http://pdbe.org/4r5w PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4r5w RCSB], [http://www.ebi.ac.uk/pdbsum/4r5w PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4r5w ProSAT]</span></td></tr> | ||
| Line 24: | Line 25: | ||
| __TOC__ | __TOC__ | ||
| </StructureSection> | </StructureSection> | ||
| + | [[Category: Human]] | ||
| [[Category: Karlberg, T]] | [[Category: Karlberg, T]] | ||
| [[Category: Schuler, H]] | [[Category: Schuler, H]] | ||
Revision as of 09:01, 22 November 2017
Human artd1 (parp1) - catalytic domain in complex with inhibitor xav939
| 
 | |||||||||||
